Navigation Links
B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership
Date:9/10/2007

vices. In addition, these solutions provide evaluation/reporting, annotation, user management, and scheduling functionality. Both of these products unequivocally lead the industry in innovation, ease of use, and market share, having been selected by 30% of all US medical schools and a growing number of hospitals and nursing programs.

Dr. Jeffrey Cooper, Executive Director of CMS, said "We are very excited to be working with B-Line Medical on this project. This is an opportunity to take our simulation activities to a new level that will benefit both simulation participants and faculty, allowing for significant performance efficiencies and ease-of-use advantages. B-Line's expertise in software development and extensive experience in developing and supporting simulation facilities make them a unique partner, which will be of great value to CMS moving forward."

For more information please visit B-Line Medical's website at: http://www.blinemedical.com

About B-Line Medical

B-Line Medical's SimCenter/SimCube solutions have been selected by top tier medical institutions as the most advanced, comprehensive and easiest to use solutions for managing clinical skills and simulation training centers. Through its sophisticated web-based architecture, the SimCenter and SimCube address the complex set of challenges associated with running standardized patient and simulation scenarios, including simultaneous monitoring of numerous locations, testing and assessment, capturing data from multiple simulators of varying types, immediate debrief of simulation participants, and realtime video annotation. These elements are bound together in simple, secure interfaces that provides aggregate reporting and streamlined facility administration, while ultimately maximizing resources and allowing faculty and staff to focus on student and curriculum development.

About the Center for Medical Simulation

The Ce
'/>"/>

SOURCE B-Line Medical
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
2. Risk of allergy more to children staying in day care centers
3. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
4. Apollo Hospital to collaborate with US cancer center to open new radiation therapy department
5. Osaka Medical Center study showed 70% of smokers couldn’t qui
6. Kalam To Lay Foundation Of Vellore Research Center
7. Free Treatment Center Established In Chennai
8. Analyzing Client-Centered Therapy.
9. New policy allows Britons to decide on treatment center
10. Turkey becoming epicenter for bird flu
11. Human Milk Center Caters To Premature Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...ion (Nasdaq: PODD ), the leader in patch pump te...stem, today announced the company will participate...nce. Management is scheduled to present an overvie...009 at The Westin St. Francis in San Francisco, CA...l information concerning the Company, its operatio...
(Date:1/7/2009)...Myers, Inc.,(NYSE: RBN ) today reported diluted ...cal first quarter ended November 30, 2008, as comp...First quarter 2009 sales increased 3% over the,pri...decreased 5% to $185,million. Excluding the impac...tion, organic sales increased 6% and organic order...
(Date:1/7/2009)...he troubles of those born at 39 weeks, , ,...g an elective repeat C-section should wait until t...ave the baby, if there are no medical issues with ...ng just two weeks earlier doubles the risk that th...ng, infection and low blood sugar, according to th...
(Date:1/7/2009)...Patients Unable to Pay Out-of-Pocket Costs, 33 Per...ERs , , SACRAMENTO, Calif., Jan. 7 The econom...tic impact on California,s community hospitals, ac...California Hospital Association (CHA). , , The r...ember 2008 among hospital chief financial officers...
Breaking Medicine News(10 mins):Health News:Robbins & Myers Announces First Quarter 2009 Results 2Health News:Robbins & Myers Announces First Quarter 2009 Results 3Health News:Robbins & Myers Announces First Quarter 2009 Results 4Health News:Robbins & Myers Announces First Quarter 2009 Results 5Health News:Robbins & Myers Announces First Quarter 2009 Results 6Health News:Robbins & Myers Announces First Quarter 2009 Results 7Health News:Robbins & Myers Announces First Quarter 2009 Results 8Health News:Robbins & Myers Announces First Quarter 2009 Results 9Health News:Early Elective C-Sections Produce Complications 2Health News:Early Elective C-Sections Produce Complications 3Health News:Economic Downturn Takes Toll on California Hospitals 2
...othing but a cosmetic nuisance. But sometimes pigm...start dividing abnormally to form a deadly form of...icans born this year will be diagnosed with melano.... Scientists know that 30 percent of all melanomas...
...o mouse chow dramatically reduced spread of aggres... compound in pill form could be used to treat huma...October 1 issue of the journal Cancer Research. Th...rsity of Arizona, is the first to show that the sy...
...nchester Been honored with a prized award for rese...ions who suffer from chronic or acute back pain wo...Best Materials Student annually at the Science, En...ar Awards has been bagged by Racheal Ambury. <...
...has come under criticism from consumer watchdog, C...irls//, preying on their fears about their bodies ...e been screened during the high-rating Australian ...de 13- to 17-year-olds and have reportedly driven ...
Other Medicine News:Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3Health News:Super Chow, Laced With Semi-Synthetic Vitamin E, Inhibited Spread of Cancer 2Health News:Super Chow, Laced With Semi-Synthetic Vitamin E, Inhibited Spread of Cancer 3Health News:Obesity Drug Advertisements Misleading Teens 2
(Date:1/6/2009)... , PARIS, France, January 6 /PRNewswire-Fir...nt to Extend the Collaboration Until,December 201...ration to Include Antibody,Discovery in Ophthalmo...nts to ExonHit if Allergan,Sublicenses to a Third... ALEHT) today announced a reinforcement,of its ex...
(Date:1/5/2009)... , BETHESDA, Md., Jan. 5 /PRNewswire-FirstC...armaceutical company developing novel, proprietary...tion and autoimmune diseases,provides an outlook..., Micromet intends to provide an update on it...ing events: , -- April 12 to 16, 2009: Upda...
(Date:1/3/2009)... , , , , , ROSEMONT, Ill., ...ce imaging (MRI) is a growing technology providing...ed in the evaluation of back pain according to an ...f the American Academy of Orthopaedic Surgeons ( h... the next several years, additional technical deve...
(Date:12/29/2008)... , BETHESDA, Md., Dec. 29 /PRNewswire-USNewswir...in Human Research Protection was announced today b...of the Health Improvement Institute. , , The w... Texas M.D. Anderson Cancer Center -- for its b...am." This program provides for 1) enhanced human ...
Breaking Medicine Technology:ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 32008 Human Research Protection Award Recipients Announced 2Actavis Receives Approval of Generic Wellbutrin XL 28R 29 300mg in the U S 25526 1Actavis Receives Approval of Generic Wellbutrin XL 28R 29 300mg in the U S 25526 2Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 1Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 2Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 3Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 4Fish cancer gene linked to pigment pattern that attracts mates 4514 1Fish cancer gene linked to pigment pattern that attracts mates 4514 22007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 12007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 22007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 3
...s., April 11, 2007 /PRNewswire-FirstCall/ --,Advan...m two,additional Phase III clinical trials of feru...erapeutic that are being,presented today at approx...ney Foundation,s Spring Clinical Meeting in Orland...estor section on the,company,s web site at <a targ...
...tion at EASL on April 13, 2007, 2007, SAN DIEGO, a...all/ -- Anadys Pharmaceuticals, Inc. and LG Life,S...dy showing that,ANA380 (LB80380) retains potency a...s (HBV) which are resistant to lamivudine,adefovi...ntation at,the 42nd Annual Meeting of the European...
Other Medicine Technology:Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 2Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 3Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 4Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 5Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 6Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 8ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 2ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 3ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 4ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 5ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 6
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 .
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
...00 Automated Microplate System, the PK CMV-PA Syst... for the detection of cytomegalovirus. Relative se...ared to EIA measures 99.8% and 99.3% respectively....ides excellent lot-to-lot consistency and eliminat...
Medicine Products: